RxDoctor Payments Data

Americo Hajaz, MD

General Practice · Lauderhill, FLNPI 1598361636

Payments from drug & device makers

$2,011in general payments, 2019–2025

Across 65 payments — averaging $30.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$357
  • Novo Nordisk$338
  • AbbVie$338
  • Shield Therapeutics Inc$233
  • Boehringer Ingelheim$199
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$166
  • plus $381 from 8 others

What the payments were for

  • Consulting fees$33817%
  • Food & beverage$1,65082%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,011 in reported general payments places this provider in the 85th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$4,142
Medicare patients
22
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin113$80,328
OzempicSemaglutide66$67,300
MounjaroTirzepatide45$47,596
EliquisApixaban24$24,471
FarxigaDapagliflozin Propanediol14$12,832
Nifedipine ErNifedipine16$934
Megestrol Acetate26$894
Cyclobenzaprine Hcl46$788
Gabapentin53$640
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide13$463
Glipizide41$431
Metoprolol Tartrate24$392
Fluticasone Propionate23$387
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)47$383
Albuterol Sulfate HfaAlbuterol Sulfate17$370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$199$80,328113 claims
Novo NordiskOzempic$338$67,30066 claims
Lilly USA, LLCMounjaro$40$47,59645 claims
PfizerEliquis$81$24,47124 claims
AstraZenecaFarxiga$357$12,83214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,901 general practice providers in Florida.

Other general practice in Lauderhill

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →